Ciltacabtagene Autoleucel (Carvykti)
BCMA-directed CAR-T cell therapy for relapsed or refractory multiple myeloma — a personalized, one-time infusion treatment.
What is Ciltacabtagene Autoleucel?
What it targets
BCMA (B-cell maturation antigen), a protein found on myeloma cells — the patient's own T cells are engineered to recognise and destroy BCMA-positive cells.
Who it may help
Adults with relapsed or refractory multiple myeloma who have received prior lines of therapy and are fit enough for CAR-T treatment at a certified centre.
Why testing matters
Organ function, prior treatment history, and disease burden are assessed before cell collection; lymphodepleting chemotherapy is given just before infusion.
Which cancers can Ciltacabtagene Autoleucel treat?
Ciltacabtagene autoleucel is approved for multiple myeloma in adults. The exact line of treatment depends on country approval and current labelling.
| Relapsed or refractory multiple myeloma | Approved for selected adults whose myeloma has returned or stopped responding after prior lines of therapy including proteasome inhibitors, immunomodulatory agents, and anti-CD38 antibodies. |
| Earlier-relapse multiple myeloma (US label) | In the US, the label includes adults after at least one prior line of therapy including a proteasome inhibitor and immunomodulatory agent, who are refractory to lenalidomide. |
| Heavily pre-treated multiple myeloma | The original FDA approval covered adults with four or more prior lines of therapy. Expanded indications now include earlier relapse settings in the US as of updated labelling. |
Who may benefit from Ciltacabtagene Autoleucel?
Doctors assess multiple factors before approving CAR-T referral. Meeting the drug label criteria is necessary but not sufficient — patient fitness and center capacity also matter.
- Adult with confirmed relapsed or refractory multiple myeloma.
- Prior treatment with a proteasome inhibitor and an immunomodulatory agent.
- Refractory to lenalidomide (per current US labelling for earlier-relapse indication).
- Adequate bone marrow, kidney, liver, heart, and lung function for CAR-T conditioning.
- No active uncontrolled infection at the time of eligibility review.
- Absence of active or recent serious autoimmune disease requiring systemic therapy.
- No prior or active CNS involvement with myeloma (varies by protocol).
- Ability to travel to and remain near a certified CAR-T center after infusion.
- Reliable caregiver available for at least four weeks post-infusion.
- No prior allogeneic stem cell transplant (eligibility may vary by center).
How does Ciltacabtagene Autoleucel work?
- BCMA targeting
- T-cell activation and expansion
- Autologous and personalized
- Lymphodepletion prepares the body
Tests needed before Ciltacabtagene Autoleucel treatment
A comprehensive workup is required before CAR-T eligibility can be confirmed. These tests assess disease status, organ function, infection risk, and fitness for the conditioning regimen.
| Bone marrow biopsy and aspirate | Confirms myeloma disease status, plasma cell percentage, and cytogenetics or FISH for risk assessment. |
| Myeloma disease markers | Serum protein electrophoresis, immunofixation, serum free light chains, immunoglobulin levels, and 24-hour urine protein electrophoresis. |
| Imaging | PET-CT, whole-body low-dose CT, or MRI depending on bone disease, extramedullary disease, or institutional protocol. |
| Full blood count and organ function panel | CBC, liver function tests, kidney function, electrolytes, LDH, coagulation tests, and albumin. |
| Infection and viral screening | Hepatitis B surface antigen and antibody, hepatitis C antibody, HIV, CMV, EBV, and other center-specific infection screening. |
| Cardiac and pulmonary assessment | Echocardiogram or MUGA scan and pulmonary function tests as required based on conditioning regimen and patient history. |
| Neurologic baseline assessment | Review of neurologic history, cognitive baseline, and examination to help detect and grade any post-infusion neurotoxicity. |
| Fertility, pregnancy, and contraception counselling | Required for patients of reproductive potential before proceeding with lymphodepleting chemotherapy and CAR-T infusion. |
How is Ciltacabtagene Autoleucel given?
Ciltacabtagene autoleucel is delivered through a multi-step CAR-T pathway at a certified treatment center. It is not a tablet or a standard infusion given in a regular oncology clinic.
| Step 1 — Leukapheresis | White blood cells are collected from the patient in a procedure called leukapheresis, usually taking 3–6 hours at an apheresis unit. |
| Step 2 — Manufacturing | Collected T cells are sent to a specialized facility where they are genetically modified, expanded, quality-tested, and released for use. This typically takes several weeks. |
| Step 3 — Bridging therapy | If needed, anti-myeloma treatment is given during the manufacturing period to prevent disease progression before CAR-T infusion. |
| Step 4 — Lymphodepleting chemotherapy | Fludarabine and cyclophosphamide are given intravenously over several days, usually starting around Day −5 to Day −3 before infusion. |
| Step 5 — CAR-T infusion | A single intravenous infusion of ciltacabtagene autoleucel is given at the certified center, typically on Day 0. |
| Step 6 — Monitoring period | Patients remain near the center for at least four weeks for daily monitoring of fever, CRS, neurologic toxicity, blood counts, and infection. |
| No repeat infusion | Ciltacabtagene autoleucel is a one-time infusion. A second infusion is not standard and would require manufacturing a new batch from new leukapheresis. |
| Duration of follow-up | Long-term follow-up continues for months to years to assess disease response, detect relapse, manage delayed side effects, and monitor for secondary malignancies. |
Potential benefits of Ciltacabtagene Autoleucel
Ciltacabtagene autoleucel has shown the ability to produce deep responses in selected patients with relapsed or refractory multiple myeloma across clinical trial programs including CARTITUDE-1 and CARTITUDE-4.
| Deep remission potential | A substantial proportion of eligible patients achieve complete response or stringent complete response, meaning myeloma becomes undetectable by standard and sensitive tests. |
| CARTITUDE-1 outcomes | The CARTITUDE-1 trial demonstrated high overall response rates in heavily pre-treated patients with four or more prior lines of therapy, with many patients achieving deep and sustained responses. |
| CARTITUDE-4 in earlier relapse | CARTITUDE-4 studied ciltacabtagene autoleucel in patients with one to three prior lines of therapy and lenalidomide-refractory disease, supporting expansion of the US label to earlier-relapse settings. |
| Treatment-free interval | For patients who achieve a deep response, there may be a meaningful period free from active anti-myeloma treatment following a single infusion. |
| One-time infusion approach | Unlike ongoing oral or injectable therapy, the CAR-T product is given once after the manufacturing and conditioning process, which may improve convenience for selected responders. |
| Option after lenalidomide refractoriness | For patients whose myeloma has become refractory to lenalidomide and other major drug classes, CAR-T offers a mechanism-distinct treatment approach. |
Individual responses vary. These outcomes represent published clinical trial data and do not guarantee individual results. Treatment decisions require specialist assessment.
Side effects of Ciltacabtagene Autoleucel
CAR-T therapy carries serious and potentially life-threatening risks that differ from conventional chemotherapy. Most serious toxicities occur in the first weeks after infusion and require close monitoring in a specialist center.
| Cytokine release syndrome (CRS) | Very common. Fever, low blood pressure, low oxygen, fast heart rate, and general illness. Most cases are grade 1–2 and manageable; severe cases require intensive care. |
| Neurologic toxicity (ICANS) | Confusion, disorientation, difficulty speaking or writing, drowsiness, and reduced alertness. Monitor daily after infusion. |
| Movement and neurocognitive toxicity | Reported specifically with BCMA-directed CAR-T therapies including Carvykti. Tremor, impaired balance, and memory or thinking changes may occur. |
| Prolonged low blood counts | Neutropenia, anemia, and thrombocytopenia are very common and may persist for weeks to months after infusion, increasing infection and bleeding risk. |
| Serious infections | Bacterial, viral, and fungal infections including opportunistic infections. Risk is increased by low neutrophil counts and hypogammaglobulinemia. |
| Hypogammaglobulinemia | Reduced immunoglobulin levels due to loss of plasma cells. May require regular intravenous immunoglobulin (IVIG) infusions after therapy. |
| Hemophagocytic lymphohistiocytosis | A rare but potentially fatal inflammatory syndrome that may overlap with severe CRS. Requires prompt recognition and specialist management. |
| Secondary malignancies | T-cell malignancies and other secondary cancers have been reported with CAR-T therapies. A long-term monitoring requirement from regulatory agencies. |
| Fatigue | Common in the weeks after infusion. May be severe and related to low blood counts, infections, or immune activation. |
| Nausea, appetite loss | Common during and after conditioning chemotherapy and in the early post-infusion period. |
Contact your doctor or emergency services immediately if you develop:
- Fever of 38°C (100.4°F) or higher at any time after infusion.
- Confusion, difficulty speaking, slurred speech, or sudden change in behavior.
- Severe shortness of breath, low oxygen, or inability to breathe comfortably.
- Inability to walk steadily, new tremor, or sudden weakness in any limb.
- Severe low blood pressure, fast heartbeat, or signs of circulatory collapse.
- Signs of serious infection: chills, rigors, or wound redness with fever.
Safety precautions and important considerations
Tell your CAR-T team about all current medical conditions, medications, supplements, and herbal products before starting any part of the CAR-T pathway.
- Report any active or recent infection, including fever, tuberculosis exposure, or known hepatitis B, hepatitis C, or HIV status.
- Inform the team about heart disease, lung disease, kidney disease, or liver disease that may affect fitness for lymphodepleting chemotherapy.
- Report any history of seizures, stroke, neuropathy, autoimmune disease, or cognitive problems that may complicate neurologic monitoring.
- Notify the team about prior stem cell transplant, prior CAR-T or bispecific antibody therapy, or prior BCMA-targeted treatment.
- Pregnancy must be excluded before starting lymphodepletion. Effective contraception is required during therapy and for the period advised by your team.
- Do not breastfeed during or after CAR-T therapy for the period specified by your oncologist.
- Avoid live vaccines before and after CAR-T therapy. Timing of other vaccines should be discussed with your team.
- Do not drive or operate heavy machinery for at least eight weeks after infusion or for as long as neurologic monitoring requires.
- Remain within one hour of the certified CAR-T center for at least four weeks after infusion, and ensure a caregiver is available at all times.
- Monitor temperature daily and report any fever promptly. Keep emergency contact numbers available at all times.
Ciltacabtagene Autoleucel treatment combinations and sequencing
Ciltacabtagene autoleucel is given as part of a structured CAR-T pathway that always includes conditioning chemotherapy. It is not combined with other anti-myeloma drugs at the time of infusion.
| Lymphodepleting chemotherapy (standard) | Fludarabine and cyclophosphamide are given before every CAR-T infusion to prepare the immune environment. This is a required component of the CAR-T pathway, not an optional add-on. |
| Bridging therapy pre-manufacturing | Anti-myeloma therapy given between leukapheresis and infusion to control disease during manufacturing. Regimen is individualized based on prior treatments and disease status. |
| Post-CAR-T options if relapse occurs | Bispecific antibodies (teclistamab, elranatamab, talquetamab), antibody-drug conjugates, or re-enrollment in a clinical trial may be considered if myeloma returns after CAR-T. |
| Clinical trial combinations | Combinations with immunomodulatory agents, PD-1 inhibitors, or other targeted therapies are being explored in trials and should only be used in a formal study setting. |
If Ciltacabtagene Autoleucel stops working
Myeloma can return after CAR-T therapy through several mechanisms. Understanding why helps determine the best next steps.
| BCMA downregulation or loss | Myeloma cells may reduce or lose BCMA expression after CAR-T exposure, making them invisible to the engineered T cells. This is the most recognized resistance mechanism. |
| CAR-T cell exhaustion or poor persistence | Infused CAR-T cells may become exhausted or fail to persist long-term, reducing ongoing anti-myeloma activity over time. |
| Antigen heterogeneity | Not all myeloma cells within the same patient may express equal BCMA levels. Cells with lower BCMA may survive initial CAR-T attack and expand. |
| Next-line options after BCMA-directed therapy | Options may include non-BCMA-targeted therapies such as talquetamab (GPRC5D), another CAR-T product with a different target, bispecific antibodies, or clinical trial enrollment. |
| Second opinion after relapse | Given the complexity of post-BCMA therapy sequencing, a second opinion from a specialized myeloma center is often valuable. |
Cost of Ciltacabtagene Autoleucel by country
The total cost of CAR-T therapy is significantly higher than most oral or injectable cancer drugs, as it includes manufacturing, hospitalization, conditioning, monitoring, and supportive care.
| United States | The CAR-T product itself carries a very high list price. Total treatment cost including hospital stay, conditioning, and monitoring can be substantially higher. Insurance coverage and Johnson & Johnson patient assistance programs are available for eligible patients. |
| European Union | Carvykti is EMA-authorized and available in some EU countries through national health systems or reimbursement programs. Coverage varies significantly by country. Self-pay access is available at specialist private centers. |
| United Kingdom | NHS England has approved Carvykti for use in selected patients. Access is through certified NHS CAR-T centers. Private access is also available at specialist centers. |
| India | Carvykti is not yet commercially approved in India. Patients may explore international referral to approved centers in the US, UK, or EU, or enrollment in clinical trials if available. |
| China | BCMA-directed CAR-T therapies are available in China through domestically developed products and approved programs. Access and cost differ from US-approved Carvykti. CancerFax can help patients explore China-based options. |
| Additional costs | Total cost includes leukapheresis, bridging therapy, lymphodepleting chemotherapy, hospital admission, ICU care if needed, blood products, IVIG, imaging, and long-term follow-up visits. |
Availability of Ciltacabtagene Autoleucel globally
Carvykti has regulatory approval in the US and EU. Access elsewhere depends on certified center infrastructure, manufacturing capacity, referral pathways, and country-specific approval.
United States
FDA-approved for selected adults with relapsed or refractory multiple myeloma. Available at FDA-certified CAR-T treatment centers. Manufacturing slots are limited and center referral is required.
European Union
EMA-authorized for multiple myeloma. Available at certified centers in several EU countries. National reimbursement varies by country — some require additional HTA approval before access.
United Kingdom
NHS England-approved for eligible patients with relapsed or refractory multiple myeloma. Delivered through certified NHS CAR-T centers. Private access also available.
India
Not yet commercially approved in India. Patients interested in Carvykti must be referred to certified centers abroad. CancerFax can assist with international coordination and eligibility review.
China
Carvykti is not NMPA-approved in China, but China has domestically approved BCMA-directed CAR-T products. CancerFax can help connect patients with China-based CAR-T programs where eligible.
Other countries
Access in Singapore, South Korea, Australia, Israel, and other regions depends on local approval status and certified center availability. Named-patient or compassionate use may be possible in some cases.
Ciltacabtagene Autoleucel in clinical trials
Multiple ongoing and completed trials continue to define the role of ciltacabtagene autoleucel in different myeloma settings, including earlier treatment lines and combination strategies.
| CARTITUDE-1 (pivotal trial) | Phase 1b/2 study in heavily pre-treated patients (four or more prior lines). Demonstrated high response rates and supported initial FDA approval. |
| CARTITUDE-4 (earlier relapse) | Phase 3 randomized study in one to three prior lines with lenalidomide-refractory disease. Supported label expansion to earlier-relapse settings in the US. |
| Frontline and high-risk myeloma | Trials are exploring Carvykti and other BCMA CAR-T therapies in newly diagnosed high-risk or transplant-ineligible patients to define earlier-line benefit. |
| Post-BCMA sequencing studies | Research is ongoing into optimal sequencing after prior BCMA-directed therapy, including bispecific antibody combinations and non-BCMA-targeted CAR-T approaches. |
| Access in India and Asia-Pacific | Selected clinical trial opportunities for BCMA-directed CAR-T therapy may be available in India and other Asian countries. CancerFax can help patients identify open trials. |
Your treatment journey with Ciltacabtagene Autoleucel
Diagnosis and disease reassessment
CAR-T eligibility assessment
Referral to certified CAR-T center
Leukapheresis — T-cell collection
Manufacturing period and bridging therapy
Lymphodepleting chemotherapy
CAR-T infusion (Day 0)
Post-infusion monitoring (weeks 1–4)
Response assessment and long-term follow-up
Questions to ask your oncologist about Ciltacabtagene Autoleucel
- Am I eligible for ciltacabtagene autoleucel given my prior treatments?
- Which certified CAR-T centers can treat me, and how long is the wait?
- What are my risks of cytokine release syndrome and neurologic toxicity?
- How long must I stay near the CAR-T center after infusion?
- What is the full expected cost, and is it covered by my insurance or government program?
- What if the manufacturing fails or my cells cannot be released?
- What are my options if CAR-T does not produce a response or if myeloma returns?
- Are there clinical trials I should consider before or instead of commercial CAR-T?
How CancerFax supports Ciltacabtagene Autoleucel patients
CancerFax helps myeloma patients and families navigate the complex CAR-T pathway — from eligibility review and specialist connection to international access and cost navigation.
| Medical records review | Upload bone marrow reports, myeloma markers, imaging, and prior treatment records. Our team reviews eligibility for ciltacabtagene autoleucel and explains what the results mean for your next steps. |
| Specialist connection | We connect myeloma patients with hematologists and CAR-T specialists experienced in Carvykti and BCMA-directed therapy at centers in India, China, the US, and Europe. |
| International treatment coordination | For patients in India or other countries where Carvykti is not yet approved, CancerFax helps coordinate international referrals to certified centers in the US, UK, or EU. |
| China CAR-T access | China has approved domestic BCMA CAR-T programs with significant clinical experience. CancerFax can help patients explore China-based CAR-T options as an alternative or parallel pathway. |
| Second opinion for relapse planning | If myeloma has returned after CAR-T or BCMA-directed therapy, CancerFax arranges specialist second opinions to help identify the best next-line strategy. |
| Cost and access navigation | We help patients understand the total cost of the CAR-T pathway, identify patient assistance programs, government schemes, or clinical trial enrollment that may reduce financial burden. |
Frequently asked questions about Ciltacabtagene Autoleucel
Common questions from myeloma patients and caregivers about Carvykti CAR-T therapy
Ciltacabtagene autoleucel (Carvykti) is a CAR-T cell therapy made from your own white blood cells, which are collected, genetically modified in a laboratory to recognize BCMA on myeloma cells, and then infused back into your body. Unlike chemotherapy, which attacks rapidly dividing cells broadly, this therapy is personalized and designed to seek out and destroy myeloma cells specifically. It is a one-time infusion, not an ongoing daily tablet.
BCMA stands for B-cell maturation antigen, a protein found on the surface of multiple myeloma cells. Because BCMA is highly expressed on myeloma cells and less so on most healthy tissues, it makes an effective target for therapies like CAR-T. Ciltacabtagene autoleucel's engineered T cells are designed to attach to BCMA and destroy cells carrying it, which is why BCMA expression testing may be part of your evaluation.
After leukapheresis (T-cell collection), the manufacturing process typically takes several weeks, as your cells are sent to a specialized facility to be modified and expanded. The timeline can vary based on manufacturing slot availability, logistics, and quality-release testing. Your care team will advise you on expected timing and whether bridging therapy is needed to control your myeloma while you wait.
Cytokine release syndrome, or CRS, occurs when the infused CAR-T cells become very active and release large amounts of inflammatory proteins called cytokines. It can cause fever, low blood pressure, low oxygen levels, and rapid heartbeat, and in severe cases requires ICU-level care. Most cases are manageable with tocilizumab and corticosteroids at a certified CAR-T centre. The Yescarta prescribing information includes a boxed warning for CRS because it can be life-threatening if not promptly treated.
If myeloma returns after CAR-T therapy, your doctor will reassess with bone marrow tests, imaging, and myeloma markers. Options may include bispecific antibodies, antibody-drug conjugates, new drug combinations, clinical trials, or other cellular therapy strategies, depending on prior treatment history, BCMA exposure, and disease characteristics. Seeking a second opinion after CAR-T relapse is often recommended given the complexity of next-step decisions.
No. Because ciltacabtagene autoleucel can cause neurologic side effects including confusion, drowsiness, tremor, and movement problems, patients are advised not to drive or operate heavy machinery for a period specified by their care team — typically at least eight weeks or longer if symptoms persist. Patients must also have a caregiver present and must remain near the certified CAR-T center for at least four weeks after infusion to allow rapid response to any toxicity.
The cost of Carvykti is substantial, covering not only the cell product itself but also leukapheresis, manufacturing, lymphodepleting chemotherapy, hospital stay, monitoring, blood products, and supportive care. In the US, insurance coverage and manufacturer patient assistance programs may reduce out-of-pocket costs for eligible patients. In other countries, access programs, clinical trial enrollment, or international treatment centers may provide cost-modified pathways. CancerFax can help patients understand their options.